findmyKOL

Robert Naismith, MD

Enriched profile

Washington University in St. Louis

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Saint Louis, MO · Midwest · United StatesSpecialtyNeurologyFocusMultiple Sclerosis Research Studies+4
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2007–2015

Robert Naismith is a Multiple Sclerosis Research Studies physician affiliated with Washington University in St. Louis. OpenAlex indexes 532 publications with 7,926 citations (h-index 50); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Robert Naismith, MD, is affiliated with Washington University in St. Louis. The public record shows 532 publications with 7,926 citations (h-index 50), centered on Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Polyomavirus and related diseases. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 27 companies, 2 NIH-funded awards (2007–2015).

  • Most recent indexed publication: 2026 · Neurology and therapy
  • Top research focus: Multiple Sclerosis Research Studies
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 27 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Sclerosis1 trialOptic Neuritis1 trialNeuritis1 trialALS

Research focus

OpenAlex concept fingerprint
Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersPolyomavirus and related diseasesAmyotrophic Lateral Sclerosis ResearchAutoimmune Neurological Disorders and Treatments

Drugs & molecules

across trials, industry payments and publications
Ocrevusgeneric · OcrelizumabClinical trials—Industry payments23Publications3Vumeritygeneric · Diroximel fumarateClinical trials—Industry payments14Publications2Zeposiageneric · OzanimodClinical trials—Industry payments15Publications1Tecfiderageneric · Dimethyl fumarateClinical trials—Industry payments11Publications3Avonexgeneric · Interferon beta-1aClinical trials—Industry payments11Publications1Upliznageneric · InebilizumabClinical trials—Industry payments34Publications—Briumvigeneric · UblituximabClinical trials—Industry payments27Publications—Tysabrigeneric · NatalizumabClinical trials—Industry payments12Publications—Kesimptageneric · OfatumumabClinical trials—Industry payments11Publications—Plegridygeneric · Peginterferon beta-1aClinical trials—Industry payments11Publications—Ensprynggeneric · SatralizumabClinical trials—Industry payments3Publications—Ponvorygeneric · PonesimodClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Genzyme CorporationClinical trials—Industry payments88Tg Therapeutics, Inc.Clinical trials—Industry payments36Horizon Therapeutics plcClinical trials—Industry payments32Sanofi-Aventis U.S. LLCClinical trials—Industry payments28Genentech USA, Inc.Clinical trials—Industry payments26Sanofi Us Services Inc.Clinical trials—Industry payments22Biogen, Inc.Clinical trials—Industry payments17Amgen Inc.Clinical trials—Industry payments16Novartis Pharmaceuticals CorporationClinical trials—Industry payments15E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments13Celgene CorporationClinical trials—Industry payments12EMD Serono, Inc.Clinical trials—Industry payments8H. Lundbeck A SClinical trials—Industry payments6Janssen Pharmaceuticals, IncClinical trials—Industry payments4Celltrion, Inc.Clinical trials—Industry payments3Alexion Pharmaceuticals, Inc.Clinical trials—Industry payments2Genentech, Inc.Clinical trials—Industry payments2AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1Banner Life Sciences, LLCClinical trials—Industry payments1BeiGene USA, Inc.Clinical trials—Industry payments1Cello Health Advantage IncClinical trials—Industry payments1Greenwich Biosciences, Inc.Clinical trials—Industry payments1Novartis Pharma AGClinical trials—Industry payments1Otsuka America Pharmaceutical, Inc.Clinical trials—Industry payments1Vertex Pharmaceuticals IncorporatedClinical trials—Industry payments1Washington University School of MedicineClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
532publications

Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.

7,926citations

Total citations across indexed works.

50h-index

Hirsch index (OpenAlex). i10-index 109.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
27companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2007–2015

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 16 Oct 2026

27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    48.8%
    Gabapentinoids14.9%
    Gabapentin80%Pregabalin21%
    Part D<11 patients
    SSRI10.2%
    Trazodone Hcl40%Paroxetine Hcl21%Fluoxetine Hcl20%Sertraline Hcl20%
    Part D<11 patients

    + 9 more classes in this area

  • Cancer & immunology

    28.1%
    Pyrimidine Synthesis Inhibitor7%
    Teriflunomide71%Aubagio29%
    Part D<11 patients
    Interferon beta5.6%
    Avonex Pen (4 Pack)46%Rebif Rebidose34%Avonex (4 Pack)20%
    Part D<11 patients

    + 5 more classes in this area

  • Musculoskeletal

    13.6%
    gamma-Aminobutyric Acid-ergic Agonist8.7%
    Baclofen100%
    Part D≥27 patients
    Muscle Relaxant2.5%
    Cyclobenzaprine Hcl100%
    Part D<11 patients

    + 1 more class in this area

All 5 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)16% facility · 84% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

2 NIH research awards on record, funded 2007–2015 per NIH RePORTER. The latest:

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Anne H. Cross72Eric C. Klawiter24Xavier Montalbán21Kathryn Trinkaus21Ellen M. Mowry17Douglas L. Arnold16Jerry S. Wolinsky16Elizabeth Fisher16Robert Bermel15Tammie L.S. Benzinger14Sheng‐Kwei Song14Andrew Goodman14Ludwig Kappos13Robert J. Fox12Junqian Xu12Stephen L. Hauser12Tjalf Ziemssen12Lauren Krupp11Hailu Chen11E.V. Appleton11James R. Williams11Samantha Lancia11Bruno Brochet11Becky Parks11Sibyl Wray11Laura Piccio10Jon Yankey10Hans‐Peter Hartung10Carrie M. Hersh10Christopher S. Coffey10Nhial T. Tutlam9Salim Chahin9Peng Sun9Fabian Model9Peter A. Calabresi9Gregory F. Wu9Enrique Álvarez9Richard A. Rudick9Jacqueline Nicholas8Kathryn C. Fitzgerald8

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/robert-naismith-md-e06895bc

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.